ScholarIQanswers from OpenAlex & ORCID
Stephan Stilgenbauer
ResearcherPublications, citations & collaboration network
Stephan Stilgenbauer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stephan Stilgenbauer have?
ScholarIQindexed works
Stephan Stilgenbauer has 1,254 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stephan Stilgenbauer have?
ScholarIQcitation count
Stephan Stilgenbauer has 75,508 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stephan Stilgenbauer?
ScholarIQh-index
Stephan Stilgenbauer has an h-index of 130 in OpenAlex.
What is the i10-index of Stephan Stilgenbauer?
ScholarIQi10-index
Stephan Stilgenbauer has an i10-index of 555 in OpenAlex.
What is the ORCID of Stephan Stilgenbauer?
ScholarIQorcid
The ORCID for Stephan Stilgenbauer is on the source record.
What is the OpenAlex record for Stephan Stilgenbauer?
ScholarIQopenalex
The OpenAlex for Stephan Stilgenbauer is on the source record.
What are the most-cited papers on Stephan Stilgenbauer?
ScholarIQmost cited works
<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael Wenger, Günter Fingerle‐Rowson, Peter Lichter, Mario Cazzola, Clemens‐Martin Wendtner, Anna Maria Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, Sebastian Böttcher, Jasmin Bahlo, Jöerg Schubert, Karl Heinz Pflüger, Silke Schott, Valentin Goede, Susanne Isfort, Julia von Tresckow, Anna‐Maria Fink, Andreas Bühler, Dirk Winkler, Karl‐Anton Kreuzer, Peter Staib, Matthias Ritgen, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Michael Hallek, Stephan Stilgenbauer, Clemens‐Martin Wendtner
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz, Alexander Kröber, Katrin Scherer, Sonja Häbe, Andreas Bühler, Axel Benner, Tina Denzel, Dirk Winkler, Jennifer Edelmann, Carsten Schwänen, Hartmut Döhner, Stephan Stilgenbauer
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, Stephan Stilgenbauer, Jasmin Bahlo, Carmen D. Schweighofer, Sebastian Böttcher, Peter Staib, Michael Kiehl, Michael J. Eckart, Gabriele Kranz, Valentin Goede, Thomas Elter, Andreas Bühler, Dirk Winkler, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Michael Hallek, Clemens‐Martin Wendtner